Ambry Genetics
Ambry Genetics is a clinical genetic diagnostics laboratory offering hereditary cancer, cardiovascular, neurological, and rare disease DNA/RNA testing through its CLIA-certified lab, serving healthcare providers, health systems, and pharmaceutical partners, and operating as a Tempus AI subsidiary.
- Company typePrivate
- Founded1999
- HeadquartersAliso Viejo, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Ambry Genetics does
Ambry Genetics is a clinical genetic diagnostics laboratory founded in 1999 and headquartered in Aliso Viejo, California, operating a CLIA-certified, CAP-accredited 65,000 sq. ft. SuperLab that has completed more than one million DNA/RNA tests across hereditary cancer, cardiology, neurology, and rare disease. Its core technology stack combines next-generation sequencing on Illumina platforms with PacBio long-read sequencing, layered with the proprietary +RNAinsight concurrent DNA/RNA testing method that identifies additional positive patients and reduces variants of uncertain significance. Supporting products include the Classifi variant classification program, the Patient for Life proactive reanalysis program, the ExomeReveal exome test with RNA analysis, and the CARE Program digital health platform that integrates with provider EMRs for automated risk screening, ordering, and result reporting.
The business generates revenue primarily through clinical genetic testing billed to insurance, with contracts covering roughly 95% of US insured lives and most patients paying $0 out of pocket; secondary streams include pharma services (companion diagnostics development, clinical trial support, real-world data) and data licensing. The go-to-market is a hybrid model: sales-led enterprise relationships with health systems (anchored by the CARE Program), healthcare provider ordering through the AmbryPort portal and paper requisitions, and channel partnerships such as AnyLabTestNow for sample collection and sponsored testing programs (AmbryLink) with biopharma companies. In February 2025, Ambry was acquired by Tempus AI for $600 million and now operates as a wholly-owned subsidiary, with Tempus reporting 23% hereditary volume growth in Q4 2025 and Ambry contributing to over 200 peer-reviewed publications that reinforce its scientific positioning. The company faces pending litigation including an Illinois GIPA class action related to genetic data transfer during the acquisition and a securities class action against Tempus citing billing practices at Ambry.
Ambry Genetics firmographics
Firmographics- Name
- Ambry Genetics
- Legal name
- Ambry Genetics
- Website
- https://ambrygen.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Ambry Genetics is a clinical genetic diagnostics laboratory offering hereditary cancer, cardiovascular, neurological, and rare disease DNA/RNA testing through its CLIA-certified lab, serving healthcare providers, health systems, and pharmaceutical partners, and operating as a Tempus AI subsidiary.
- Ownership category
- akta.pro rank
Ambry Genetics industry classification
Industry- Product category
- Clinical Genetic Testing
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where Ambry Genetics is headquartered
LocationHeadquarters
- HQ city
- Aliso Viejo
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Ambry Genetics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Clinical Genetic Testing Services: Ambry generates revenue through clinical genetic testing for hereditary cancer, cardiology, neurology, and rare diseases. Tests are billed to insurance (with majority of US health plans contracted), with 4 out of 5 patients paying $0 on average due to insurance coverage. For uninsured or those not using insurance, self-pay pricing is available.
- Pharma Services: Ambry provides genetic testing services to pharmaceutical companies for drug development, clinical trial support and patient identification, real-world data services, and companion diagnostics development. Supports therapeutic areas including oncology, neurology, cardiovascular diseases, gene therapy, gastroenterology, and rare diseases.
- Data Licensing: Ambry generates revenue through licensing its genetic data assets to pharmaceutical and research partners for drug discovery and development purposes. The company has contributed to research published in Nature Communications on variant effect analysis.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Per test | Standard insurance-covered testing (majority of patients) |
| One time/ perpetual license | Pay-as-you-go | Self-pay pricing for uninsured patients |
| Hybrid | Annual | Financial Assistance Program |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
Ambry Genetics product offering
Product offeringCore offering
Ambry Genetics operates one of the largest clinical genetic testing laboratories in the world, providing hereditary cancer, cardiovascular, neurological, and rare disease genetic testing from a 65,000 sq. ft. CLIA-certified, CAP-accredited facility in Aliso Viejo, CA. The laboratory offers proprietary paired DNA/RNA testing (+RNAinsight), exome-based testing (ExomeReveal), the Patient for Life proactive reanalysis program, the CARE Program digital health platform, companion diagnostics development, and pharma research services.
Product overview
Ambry Genetics offers a comprehensive clinical genetic testing platform with multiple interconnected products and services. The core testing portfolio spans four main areas: Oncology (hereditary cancer panels with +RNAinsight®), Cardiology, Neurology, and Clinical Genomics (exome testing with ExomeReveal®). Key platform features include the CARE Program® for patient identification and workflow automation, Patient for Life Program™ for proactive reanalysis, Classifi® for variant classification, and AmbryPort® for online ordering. Additional services include pharma partnerships, telemedicine counseling, insurance pre-verification, and sponsored testing through AmbryLink. The company pioneered paired DNA/RNA testing with +RNAinsight® and offers the largest genetic sequencing lab in the world (SuperLab).
Differentiator
Problem solved
Functional benefit
Brands
- +RNAinsight®: Concurrent DNA/RNA testing technology that analyzes functional RNA data to help detect and classify DNA variants, identifying more positive results and resolving variants of uncertain significance.
- Patient for Life Program™
- ExomeReveal®
- CARE Program®
- Classifi®
- AmbryPort®
- AmbryLink
Products and services
- Hereditary Cancer Test Menu Clinical genetic testing panels for hereditary cancer syndromes, including BRCA1/2 testing, offered to healthcare providers for patient diagnosis, treatment planning, and risk assessment.
- Cardiology Test Menu Hereditary cardiovascular genetic testing panels for inherited heart conditions, providing diagnostic insights for cardiomyopathies, arrhythmias, aortopathies, and familial hypercholesterolemia.
- Neurology Test Menu Hereditary neurological genetic testing for neurodevelopmental, neuromuscular, movement, and seizure disorders, supporting diagnosis of pediatric and adult neurological conditions.
- Clinical Genomics Test Menu Exome sequencing and rare disease testing for unresolved clinical cases, including trio-based exome testing and family variant testing to identify the genetic basis of rare conditions.
- +RNAinsight Concurrent DNA and RNA testing add-on that analyzes both genomic and transcriptomic data to improve variant interpretation, identifying approximately 1 in 25 positive patients missed by DNA-only testing and reducing variants of uncertain significance by 6%.
- Patient for Life Program Proactive reanalysis program that re-evaluates exome data as new scientific discoveries emerge, providing additional diagnoses for approximately 5% of initially negative patients without requiring a new sample.
- ExomeReveal Exome sequencing combined with RNA analysis to provide enhanced diagnostic insights for rare disease cases, integrating transcriptomic data with genomic findings.
- CARE Program Digital health solution that analyzes electronic medical record (EMR) data to identify at-risk patients who qualify for genetic testing, integrating into health system workflows to streamline patient identification, consent, and testing.
- Pharma Services Genetic testing and genomic research services for pharmaceutical companies supporting drug development, clinical trials, real-world data generation, and data licensing initiatives.
- Companion Diagnostics Development and validation of companion diagnostic tests to identify patients likely to respond to specific targeted therapies, supporting pharmaceutical partners in precision medicine programs.
- AmbryLink Sponsored genetic testing programs that enable pharmaceutical and biotech companies to fund no-cost genetic testing for patients meeting specific clinical criteria.
- Telemedicine Genetic Counseling Board-certified genetic counseling services delivered via telemedicine to support patients and providers in interpreting genetic test results and understanding implications.
- Sample Collection Kit Delivery Direct-to-patient and direct-to-provider shipping of sample collection kits for saliva and blood samples, supporting remote specimen collection across the United States and Canada.
Quantifiable outcome
- 1 in 25 positive patients would have been missed without RNA data (using +RNAinsight)
- +4 more outcomes
Companies that use Ambry Genetics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
Ambry Genetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
Ambry Genetics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Child Neurology FoundationcoreAmbry Genetics named Champion Level Partner of the Child Neurology Foundation, supporting the foundation's education initiatives and resources for families and healthcare professionals in pediatric neurology. The partnership aims to advance earlier diagnosis and strengthen care through evidence-based education, diagnostics, and resources.
- Genome MedicalcorePartnership with Genome Medical, a nationwide specialty medical practice focused on genetic counseling, to provide expert genetic consultations for patients who may be at risk for common hereditary cancers. Genome Medical genetic experts and primary care MDs work with patients to determine whether genetic testing is appropriate.
- MDxHealthminorPartnership with MDxHealth to increase genetic testing within the urology market.
- AnyLabTestNowminorPartnership with AnyLabTestNow for local laboratory sample collection services, enabling patients to visit nearby locations for blood draws.
- PRECEDE ConsortiumcorePartnership with REALM IDx (parent company of Ambry Genetics) and PRECEDE Consortium to bring expertise in genetic testing, pathology, and imaging to determine who is at elevated risk for pancreatic cancer and invite high-risk individuals into state-of-the-art clinical screening programs.
- Arrowhead PharmaceuticalscoreFCS Seek program - Arrowhead Pharmaceutical Program offers confidential genetic testing for patients with clinical history of severe hypertriglyceridemia, testing for underlying genetic causes like Familial Chylomicronemia Syndrome (FCS) and hyperlipoproteinemia.
- Rocket PharmaceuticalscoreMission: Genome Danon Disease Genetic Testing Program - testing for patients under 40 years of age meeting select eligibility utilizing Ambry's CardioNext testing panel.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Ambry Genetics competitors and assessment
Company assessmentDirect peers
- Caris Life Sciences: Caris is a molecular science competitor with commercial overlap with Ambry in oncology testing and an existing mutual commercial partnership. It competes for oncology hereditary and somatic testing volume.
- GeneDx: GeneDx is one of Ambry's closest direct competitors, offering hereditary cancer, rare disease exome, and pediatric genetics testing through a CLIA-certified lab. The two compete head-to-head on hereditary cancer panels and exome-based diagnostics for US providers.
- Natera: Natera competes with Ambry in hereditary cancer testing (Empower genetics) and oncology molecular diagnostics, with overlapping hospital and oncologist customer segments.
- Veracyte: Veracyte is an oncology molecular diagnostics competitor with growing hereditary and somatic oncology franchises. It overlaps with Ambry in oncology genetic insights for providers and health systems.
- NeoGenomics: NeoGenomics provides oncology-focused genetic and molecular testing serving community oncologists and hospitals, competing with Ambry's oncology test menu for the same provider customer base.
- Myriad Genetics: Myriad is a legacy leader in hereditary cancer testing (BRACAnalysis, myRisk) and competes with Ambry in hereditary cancer panels, with overlapping target customers among oncologists, breast centers, and OB/GYNs.
Emerging players
- Color Health: Color offers hereditary cancer and population genetic testing with a digital-first model and employer/payer channels. It overlaps with Ambry on hereditary cancer testing but differentiates through consumer/employer distribution rather than provider referrals.
Regional players
- Centogene: Centogene focuses on rare disease diagnostics and hereditary testing primarily in Europe, the Middle East, and LatAm. It is a direct competitor in rare disease exome testing but operates in geographies where Ambry does not currently accept orders.
Broad incumbents
- Laboratory Corporation of America (Labcorp): Labcorp offers hereditary cancer and rare disease genetic testing alongside its broader clinical lab menu, competing with Ambry for health-system and physician office volume, particularly on integrated lab contracts.
- Quest Diagnostics: Quest offers hereditary cancer and pharmacogenomic testing as part of its broader diagnostic menu. It is a broad incumbent with extensive US payer relationships that overlap with Ambry's distribution, though it does not specialize in Ambry's exome + RNA niche.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Ambry Genetics social profiles
Digital presenceAmbry Genetics compliance and trust
Trust signalCompliance7 records
Ambry Genetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ambry Genetics leadership team
Management profileNumber of profiles
Profiles9 records
Ambry Genetics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ambry Genetics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ambry Genetics
What does Ambry Genetics do?
Ambry Genetics operates one of the largest clinical genetic testing laboratories in the world, providing hereditary cancer, cardiovascular, neurological, and rare disease genetic testing from a 65,000 sq. ft. CLIA-certified, CAP-accredited facility in Aliso Viejo, CA. The laboratory offers proprietary paired DNA/RNA testing (+RNAinsight), exome-based testing (ExomeReveal), the Patient for Life proactive reanalysis program, the CARE Program digital health platform, companion diagnostics development, and pharma research services.
Is Ambry Genetics a public or private company?
Ambry Genetics is a private company. It is classified as corporate owned and is currently operating.
When was Ambry Genetics founded?
Ambry Genetics was founded in 1999. It employs 251 to 500 people.
Where is Ambry Genetics based?
Ambry Genetics is headquartered in Aliso Viejo, United States, in the North America region.
How does Ambry Genetics make money?
Three revenue lines are on record. Clinical Genetic Testing Services are the primary driver. The others are pharma Services and data Licensing.
Who are Ambry Genetics's main competitors?
Direct peers on record are Caris Life Sciences, GeneDx, Natera, Veracyte, NeoGenomics and Myriad Genetics. Color Health is listed as an emerging player. Centogene is listed as a regional player. Broad incumbents are Laboratory Corporation of America (Labcorp) and Quest Diagnostics.
Does Ambry Genetics have an API?
No public API is recorded for Ambry Genetics.
What industry is Ambry Genetics in?
Ambry Genetics's product category is Clinical Genetic Testing. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.